These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 29902402)

  • 1. Survival studies: competing risks, immortality and censoring.
    Barnett AG; Oldmeadow C; Attia JR
    Med J Aust; 2018 Jun; 208(11):475-477. PubMed ID: 29902402
    [No Abstract]   [Full Text] [Related]  

  • 2. Missing covariates in competing risks analysis.
    Bartlett JW; Taylor JM
    Biostatistics; 2016 Oct; 17(4):751-63. PubMed ID: 27179002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A proportional hazards regression model for the subdistribution with right-censored and left-truncated competing risks data.
    Zhang X; Zhang MJ; Fine J
    Stat Med; 2011 Jul; 30(16):1933-51. PubMed ID: 21557288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Applications of statistics to medical science, IV survival analysis.
    Watanabe H
    J Nippon Med Sch; 2012; 79(3):176-81. PubMed ID: 22791117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Doubly robust estimation of attributable fractions in survival analysis.
    Sjölander A; Vansteelandt S
    Stat Methods Med Res; 2017 Apr; 26(2):948-969. PubMed ID: 25519888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The importance of censoring in competing risks analysis of the subdistribution hazard.
    Donoghoe MW; Gebski V
    BMC Med Res Methodol; 2017 Apr; 17(1):52. PubMed ID: 28376736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Practical Overview and Reporting Strategies for Statistical Analysis of Survival Studies.
    Dey T; Mukherjee A; Chakraborty S
    Chest; 2020 Jul; 158(1S):S39-S48. PubMed ID: 32658651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. When do we need competing risks methods for survival analysis in nephrology?
    Noordzij M; Leffondré K; van Stralen KJ; Zoccali C; Dekker FW; Jager KJ
    Nephrol Dial Transplant; 2013 Nov; 28(11):2670-7. PubMed ID: 23975843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subdistribution hazard models for competing risks in discrete time.
    Berger M; Schmid M; Welchowski T; Schmitz-Valckenberg S; Beyersmann J
    Biostatistics; 2020 Jul; 21(3):449-466. PubMed ID: 30418529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statistical Methods for Cardiovascular Researchers.
    Moyé L
    Circ Res; 2016 Feb; 118(3):439-53. PubMed ID: 26846639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biostatistics pitfalls: Lessons learned from analysis of medical data.
    Yin G; Zhang C; Yang Z
    Contemp Clin Trials; 2019 Dec; 87():105875. PubMed ID: 31676313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A joint frailty-copula model between tumour progression and death for meta-analysis.
    Emura T; Nakatochi M; Murotani K; Rondeau V
    Stat Methods Med Res; 2017 Dec; 26(6):2649-2666. PubMed ID: 26384516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strategies for power calculations in predictive biomarker studies in survival data.
    Chen DT; Huang PY; Lin HY; Haura EB; Antonia SJ; Cress WD; Gray JE
    Oncotarget; 2016 Dec; 7(49):80373-80381. PubMed ID: 27661007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correcting for dependent censoring in routine outcome monitoring data by applying the inverse probability censoring weighted estimator.
    Willems S; Schat A; van Noorden MS; Fiocco M
    Stat Methods Med Res; 2018 Feb; 27(2):323-335. PubMed ID: 26988930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hierarchical likelihood inference on clustered competing risks data.
    Christian NJ; Ha ID; Jeong JH
    Stat Med; 2016 Jan; 35(2):251-67. PubMed ID: 26278918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Semiparametric accelerated failure time cure rate mixture models with competing risks.
    Choi S; Zhu L; Huang X
    Stat Med; 2018 Jan; 37(1):48-59. PubMed ID: 28983935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. On the Plackett distribution with bivariate censored data.
    Ghosh D
    Int J Biostat; 2008; 4(1):Article 7. PubMed ID: 22462114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Model evaluation based on the negative predictive value for interval-censored survival outcomes.
    Han S; Tsui KW; Andrei AC
    Stat Methods Med Res; 2017 Apr; 26(2):661-673. PubMed ID: 25305195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time-to-Event Modeling of Left- or Right-Censored Toxicity Data in Nonclinical Drug Toxicology.
    Berges A; Cerou M; Sahota T; Liefaard L; Ambery C; Zamuner S; Chen C; Hénin E
    Toxicol Sci; 2018 Sep; 165(1):50-60. PubMed ID: 29788384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Statistics Commentary Series. Commentary No. 38: Simpson's Paradox and the Mantel-Haenszel χ2.
    Streiner DL
    J Clin Psychopharmacol; 2020; 40(2):109-111. PubMed ID: 32068566
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.